IP Library › Granted Patent US 11,773,108
Granted Patent B2
US 11,773,108 · App. 17/751,035 · Granted Oct 3, 2023

Indene derivatives useful in treating pain and inflammation

Inventors: Curtis Harwig (Vancouver, CA); Jeremy D. Pettigrew (Vancouver, CA); Jennifer Cross (Vancouver, CA); Jeyaprakashnarayanan Seenisamy (Vancouver, CA); Mahesh Narayan Keregadde (Vancouver, CA); Karthikeyan Iyanar (Vancouver, CA)
Assignee: Taro Pharmaceuticals Inc.
C07D493/10A61P29/00C07D231/54C07D401/08C07D403/08C07D417/08
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,773,108
App. No.
17/751,035
Granted
Oct 3, 2023
Kind
B2
Abstract

Compounds of formula (1): wherein, R 1 , R 2 , R 3 , R 4a , R 4b and R 5 are described herein, or a stereoisomer, enantiomer or tautomer thereof or mixtures thereof, or a pharmaceutically acceptable salt or solvate thereof, are described herein, as well as other compounds. These compounds are useful in treating inflammation and/or pain. Compositions comprising a compound of the invention are also disclosed, as are methods of using the compounds to treat inflammation and/or pain.

Claims (162)

1. A method of treating inflammation and/or pain inflammation and/or pain caused by colitis, cystitis, chronic prostatitis or chronic pelvic pain, osteoarthritis, inflammatory pain, hyperalgesia, neuropathic pain, and/or pulmonary inflammation or fibrosis,

the method comprising administering a therapeutically effective amount of a pharmaceutical composition comprising a compound of formula (I), or a stereoisomer, enantiomer or tautomer thereof or mixtures thereof, or a pharmaceutically acceptable salt or solvate thereof, to a mammal in need thereof,

wherein the mammal has inflammation and/or pain caused by colitis, cystitis, chronic prostatitis or chronic pelvic pain, osteoarthritis, inflammatory pain, hyperalgesia, neuropathic pain, and/or pulmonary inflammation or fibrosis,

wherein formula (I) is:

wherein:

is an optionally substituted fused 5- or 6-membered N-heteroaryl;

R 1 is hydrogen;

R 2 is —R 6 —OR 7 ;

R 3 is —R 6 —OR 7 or —R 6 —N(R 8 ) 2 ;

R 4a is —R 9 —OR 7 and R 4b is hydrogen, alkyl or optionally substituted heteroaryl;

or R 4a is an optionally substituted aryl and R b is a bond to C16;

or R 4a and R 4b together form alkylidene, provided that

is a fused 5- or 6-membered N-heteroaryl substituted by substituted aryl, substituted aralkyl, substituted cycloalkyl or substituted heteroaryl;

or R 4a is alkyl and R 4b is hydrogen, provided that

is a fused 5- or 6-membered N-heteroaryl substituted by substituted aryl, substituted aralkyl, substituted cycloalkyl or substituted heteroaryl;

or R 4 and R 1 together form an optionally substituted bicyclic heterocyclyl and R b is hydrogen;

or R 4a , R 4b and R 1 together form a fused optionally substituted heteroaryl;

R 5 is alkyl or R 5 is a direct bond to the carbon at C14;

each R 6 is independently selected from a direct bond or a straight or branched alkylene chain;

each R 7 is independently selected from hydrogen or alkyl;

each R 8 is independently selected from hydrogen or alkyl; and

R 9 is a direct bond or a straight or branched alkylene chain;

or a stereoisomer, enantiomer or tautomer thereof or mixtures thereof, or a pharmaceutically acceptable salt or solvate thereof.

2. The method of claim 1 wherein in formula (I):

is an optionally substituted fused 5- or 6-membered N-heteroaryl;

R 1 is hydrogen;

R 2 is —R 6 —OR 7 ;

R 3 is —R 6 —OR 7 or —R 6 —N(R 8 ) 2 ;

R 4 is —R 9 —OR 7 and R 4b is hydrogen, alkyl or optionally substituted heteroaryl;

R 5 is alkyl or R 5 is a direct bond to the carbon at C14;

each R 6 is independently selected from a direct bond or a straight or branched alkylene chain;

each R 7 is independently selected from hydrogen or alkyl;

each R 8 is independently selected from hydrogen or alkyl; and

R 9 is a direct bond or a straight or branched alkylene chain.

3. The method of claim 2 wherein the compound of formula (I) is selected from:

(1S,3aS,4R,5S,7aS)-4-(hydroxymethyl)-5-((5R,6S)-6-(hydroxymethyl)-5-methyl-4,5,6,7-tetrahydro-1H-indazol-5-yl)-7a-methyloctahydro-1H-inden-1-ol;

(1R,3aS,4R,5S,7aS)-4-(hydroxymethyl)-5-((5R,6S)-6-(hydroxymethyl)-5-methyl-4,5,6,7-tetrahydro-1H-indazol-5-yl)-7a-methyloctahydro-1H-inden-1-ol;

(1S,3aS,4R,5S,7aS)-4-(hydroxymethyl)-5-((5R,6S)-6-(hydroxymethyl)-5-methyl-4,5,6,7-tetrahydro-1H-indazol-5-yl)-1,7a-dimethyloctahydro-1H-inden-1-ol;

(1S,3aS,4R,5S,7aS)-4-(hydroxymethyl)-5-((5R,6S)-6-(hydroxymethyl)-5-methyl-4,5,6,7-tetrahydro-1H-indazol-5-yl)-7a-methyl-1-(pyridin-2-yl)octahydro-1H-inden-1-ol;

(1S,3aS,4R,5S,7aS)-4-(hydroxymethyl)-5-((5R,6S)-6-(hydroxymethyl)-5-methyl-4,5,6,7-tetrahydro-1H-indazol-5-yl)-7a-methyl-1-(thiazol-2-yl)octahydro-1H-inden-1-ol;

(1S,3aS,4R,5S,7aS)-4-(aminomethyl)-5-((5R,6S)-6-(hydroxymethyl)-5-methyl-4,5,6,7-tetrahydro-1H-indazol-5-yl)-7a-methyl-1-(thiazol-2-yl)octahydro-1H-inden-1-ol; and

(1S,3aS,4R,5S,7aS)-4-(aminomethyl)-5-((5R,6S)-6-(hydroxymethyl)-5-methyl-4,5,6,7-tetrahydro-1H-indazol-5-yl)-7a-methyl-1-(pyridin-2-yl)octahydro-1H-inden-1-ol.

4. The method of claim 2 wherein the compound of formula (I) is:

(2S,5R)-5-ethyl-2-((1R,3aS,4S,5S,7aS)-4-(hydroxymethyl)-5-((5R,6S)-6-(hydroxymethyl)-5-methyl-4,5,6,7-tetrahydro-1H-indazol-5-yl)-7a-methyloctahydro-1H-inden-1-yl)-6-methylheptan-3-ol.

5. The method of claim 1 wherein in formula (I):

is an optionally substituted fused 5- or 6-membered N-heteroaryl;

R 1 is hydrogen;

R 2 is —R 6 —OR 7 ;

R 3 is —R 6 —OR 7 or —R 6 —N(R 8 ) 2 ;

R 4a and R 1 together form an optionally substituted bicyclic heterocyclyl and R 4b is hydrogen;

R 5 is alkyl or R 5 is a direct bond to the carbon at C14;

each R 6 is independently selected from a direct bond or a straight or branched alkylene chain;

each R 7 is independently selected from hydrogen or alkyl; and

each R 8 is independently selected from hydrogen or alkyl.

6. The method of claim 5 wherein the compound of formula (I) is selected from:

((5R,6S)-5-((2R,3S,3aR,3bS,5′R,6S,7R,7aS,8aS)-7-(hydroxymethyl)-3,3b,5′-trmethyltetradecahydrospiro[indeno[2,1-b]furan-2,2′-pyran]-6-yl)-5-methyl-4,5,6,7-tetrahydro-1H-indazol-6-yl)methanol; and

((5R,6S)-5-((2R,3S,3aR,3bS,5′R,6S,7R,7aS,8aS)-7-(aminomethyl)-3,3b,5′-trmethyltetradecahydrospiro[indeno[2,1-b]furan-2,2′-pyran]-6-yl)-5-methyl-4,5,6,7-tetrahydro-1H-indazol-6-yl)methanol.

7. The method of claim 1 wherein in formula (I):

is an optionally substituted fused 5- or 6-membered N-heteroaryl;

R 1 is hydrogen;

R 2 is —R 6 —OR 7 ;

R 3 is —R 6 —OR 7 or —R 6 —N(R 8 ) 2 ;

or R 4a , R 4b and R 1 together form a fused optionally substituted heteroaryl;

R 5 is alkyl or R 5 is a direct bond to the carbon at C14;

each R 6 is independently selected from a direct bond or a straight or branched alkylene chain;

each R 7 is independently selected from hydrogen or alkyl; and

each R 8 is independently selected from hydrogen or alkyl.

8. The method of claim 7 wherein the compound of formula (I) is selected from:

((4aS,5R,6S,8aS)-6-((5R,6S)-6-(hydroxymethyl)-5-methyl-4,5,6,7-tetrahydro-1H-indazol-5-yl)-8a-methyl-1,4,4a,5,6,7,8,8a-octahydroindeno[1,2-c]pyrazol-5-yl)methanol;

((5R,6S)-5-((4aS,5R,6S,8aS)-5-(aminomethyl)-8a-methyl-1,4,4a,5,6,7,8,8a-octahydroindeno[1,2-c]pyrazol-6-yl)-5-methyl-4,5,6,7-tetrahydro-1H-indazol-6-yl)methanol;

((5R,6S)-5-((5aS,6R,7S,9aS)-6-(aminomethyl)-9a-methyl-5a,6,7,8,9,9a-hexahydro-5H-indeno[1,2-b]pyridin-7-yl)-5-methyl-4,5,6,7-tetrahydro-1H-indazol-6-yl)methanol; and

((5aS,6R,7S,9aS)-7-((5R,6S)-6-(hydroxymethyl)-5-methyl-4,5,6,7-tetrahydro-1H-indazol-5-yl)-9a-methyl-5a,6,7,8,9,9a-hexahydro-5H-indeno[1,2-b]pyridin-6-yl)methanol.

9. The method of claim 1 wherein in formula (I):

is an optionally substituted fused 5- or 6-membered N-heteroaryl;

R 1 is hydrogen;

R 2 is —R 6 —OR 7 ;

R 3 is —R 6 —OR 7 or —R 6 —N(R 8 ) 2 ;

R 4a is an optionally substituted aryl and R b is a bond to C16.

R 5 is alkyl or R 5 is a direct bond to the carbon at C14;

each R 6 is independently selected from a direct bond or a straight or branched alkylene chain;

each R 7 is independently selected from hydrogen or alkyl; and

each R 8 is independently selected from hydrogen or alkyl.

10. The method of claim 9 wherein the compound of formula (I) is selected from:

((5R,6S)-5-((3aS,6S,7R,7aS)-7-(aminomethyl)-3a-methyl-3-phenyl-3a,4,5,6,7,7a-hexahydro-1H-inden-6-yl)-5-methyl-4,5,6,7-tetrahydro-1H-indazol-6-yl)methanol; and

((5R,6S)-5-((3aS,6S,7R,7aS)-7-(hydroxymethyl)-3a-methyl-3-phenyl-3a,4,5,6,7,7a-hexahydro-1H-inden-6-yl)-5-methyl-4,5,6,7-tetrahydro-1H-indazol-6-yl)methanol.

11. The method of claim 1 wherein in formula (I):

is a fused 5- or 6-membered N-heteroaryl substituted by substituted aryl, substituted aralkyl, substituted cycloalkyl or substituted heteroaryl;

R 1 is hydrogen;

R 2 is —R 6 —OR 7 ;

R 3 is —R 6 —OR 7 or —R 6 —N(R 8 ) 2 ;

R 4a and R 4b together form alkylidene;

R 5 is alkyl or R 5 is a direct bond to the carbon at C14;

each R 6 is independently selected from a direct bond or a straight or branched alkylene chain;

each R 7 is independently selected from hydrogen or alkyl; and

each R 8 is independently selected from hydrogen or alkyl.

12. The method of claim 11 wherein the compound of formula (I) is selected from:

((5R,6S)-5-((3aS,4R,5S,7aS)-4-(aminomethyl)-7a-methyl-1-methyleneoctahydro-1H-inden-5-yl)-1-(4-fluorophenyl)-5-methyl-4,5,6,7-tetrahydro-1H-indazol-6-yl)methanol;

4-(4-((5R,6S)-5-((3aS,4R,5S,7aS)-4-(aminomethyl)-7a-methyl-1-methyleneoctahydro-1H-inden-5-yl)-6-(hydroxymethyl)-5-methyl-4,5,6,7-tetrahydro-1H-indazol-1-yl)phenoxy)benzoic acid;

((5R,6S)-5-((3aS,4R,5S,7aS)-4-(aminomethyl)-7a-methyl-1-methyleneoctahydro-1H-inden-5-yl)-2-(4-methoxyphenyl)-5-methyl-4,5,6,7-tetrahydro-2H-indazol-6-yl)methanol;

((5R,6S)-5-((3aS,4R,5S,7aS)-4-(aminomethyl)-7a-methyl-1-methyleneoctahydro-1H-inden-5-yl)-2-(4-fluorophenyl)-5-methyl-4,5,6,7-tetrahydro-2H-indazol-6-yl)methanol;

(4-((5R,6S)-5-((3aS,4R,5S,7aS)-4-(aminomethyl)-7a-methyl-1-methyleneoctahydro-1H-inden-5-yl)-6-(hydroxymethyl)-5-methyl-4,5,6,7-tetrahydro-1H-indazol-1-yl)phenyl)(phenyl)methanone;

((5R,6S)-5-((3aS,4R,5S,7aS)-4-(aminomethyl)-7a-methyl-1-methyleneoctahydro-1H-inden-5-yl)-1-(2-fluorophenyl)-5-methyl-4,5,6,7-tetrahydro-1H-indazol-6-yl)methanol;

((5R,6S)-5-((3aS,4R,5S,7aS)-4-(aminomethyl)-7a-methyl-1-methyleneoctahydro-1H-inden-5-yl)-1-(2,4-difluorophenyl)-5-methyl-4,5,6,7-tetrahydro-1H-indazol-6-yl)methanol;

((5R,6S)-5-((3aS,4R,5S,7aS)-4-(aminomethyl)-7a-methyl-1-methyleneoctahydro-1H-inden-5-yl)-1-(3,4-difluorophenyl)-5-methyl-4,5,6,7-tetrahydro-1H-indazol-6-yl)methanol;

((5R,6S)-5-((3aS,4R,5S,7aS)-4-(aminomethyl)-7a-methyl-1-methyleneoctahydro-1H-inden-5-yl)-1-(3-fluorophenyl)-5-methyl-4,5,6,7-tetrahydro-1H-indazol-6-yl)methanol;

((5R,6S)-5-((3aS,4R,5S,7aS)-4-(aminomethyl)-7a-methyl-1-methyleneoctahydro-1H-inden-5-yl)-2-(3,4-difluorophenyl)-5-methyl-4,5,6,7-tetrahydro-2H-indazol-6-yl)methanol;

((5R,6S)-5-((3aS,4R,5S,7aS)-4-(aminomethyl)-7a-methyl-1-methyleneoctahydro-1H-inden-5-yl)-2-(4-fluorophenyl)-5-methyl-4,5,6,7-tetrahydro-2H-indazol-6-yl)methanol;

((5R,6S)-5-((3aS,4R,5S,7aS)-4-(aminomethyl)-7a-methyl-1-methyleneoctahydro-1H-inden-5-yl)-2-(4-(4-fluorophenoxy)phenyl)-5-methyl-4,5,6,7-tetrahydro-2H-indazol-6-yl)methanol;

((5R,6S)-5-((3aS,4R,5S,7aS)-4-(aminomethyl)-7a-methyl-1-methyleneoctahydro-1H-inden-5-yl)-5-methyl-1-(4-phenoxyphenyl)-4,5,6,7-tetrahydro-1H-indazol-6-yl)methanol;

((5R,6S)-5-((3aS,4R,5S,7aS)-4-(aminomethyl)-7a-methyl-1-methyleneoctahydro-1H-inden-5-yl)-1-(4-(4-fluorophenoxy)phenyl)-5-methyl-4,5,6,7-tetrahydro-1H-indazol-6-yl)methanol;

((5R,6S)-5-((3aS,4R,5S,7aS)-4-(aminomethyl)-7a-methyl-1-methyleneoctahydro-1H-inden-5-yl)-5-methyl-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydro-2H-indazol-6-yl)methanol;

(4-((5R,6S)-5-((3aS,4R,5S,7aS)-4-(aminomethyl)-7a-methyl-1-methyleneoctahydro-1H-inden-5-yl)-6-(hydroxymethyl)-5-methyl-4,5,6,7-tetrahydro-2H-indazol-2-yl)phenyl)(phenyl)methanone;

((5R,6S)-5-((3aS,4R,5S,7aS)-4-(aminomethyl)-7a-methyl-1-methyleneoctahydro-1H-inden-5-yl)-2-(2-fluorophenyl)-5-methyl-4,5,6,7-tetrahydro-2H-indazol-6-yl)methanol;

((5R,6S)-5-((3aS,4R,5S,7aS)-4-(aminomethyl)-7a-methyl-1-methyleneoctahydro-1H-inden-5-yl)-2-(2,4-difluorophenyl)-5-methyl-4,5,6,7-tetrahydro-2H-indazol-6-yl)methanol;

4-(4-((5R,6S)-5-((3aS,4R,5S,7aS)-4-(aminomethyl)-7a-methyl-1-methyleneoctahydro-1H-inden-5-yl)-6-(hydroxymethyl)-5-methyl-4,5,6,7-tetrahydro-2H-indazol-2-yl)phenoxy)benzoic acid;

((5R,6S)-5-((3aS,4R,5S,7aS)-4-(aminomethyl)-7a-methyl-1-methyleneoctahydro-1H-inden-5-yl)-2-(3-fluorophenyl)-5-methyl-4,5,6,7-tetrahydro-2H-indazol-6-yl)methanol;

(4-((5R,6S)-5-((3aS,4R,5S,7aS)-4-(aminomethyl)-7a-methyl-1-methyleneoctahydro-1H-inden-5-yl)-6-(hydroxymethyl)-5-methyl-4,5,6,7-tetrahydro-1H-indazol-1-yl)phenyl)(4-(pent-4-yn-1-yloxy)phenyl)methanone;

(4-((5R,6S)-5-((3aS,4R,5S,7aS)-4-(aminomethyl)-7a-methyl-1-methyleneoctahydro-1H-inden-5-yl)-6-(hydroxymethyl)-5-methyl-4,5,6,7-tetrahydro-2H-indazol-2-yl)phenyl)(4-(pent-4-yn-1-yloxy)phenyl)methanone;

4-((5R,6S)-5-((3aS,4R,5S,7aS)-4-(aminomethyl)-7a-methyl-1-methyleneoctahydro-1H-inden-5-yl)-6-(hydroxymethyl)-5-methyl-4,5,6,7-tetrahydro-1H-indazol-1-yl)benzoic acid; and

4-((5R,6S)-5-((3aS,4R,5S,7aS)-4-(aminomethyl)-7a-methyl-1-methyleneoctahydro-1H-inden-5-yl)-6-(hydroxymethyl)-5-methyl-4,5,6,7-tetrahydro-2H-indazol-2-yl)benzoic acid.

13. The method of claim 11 wherein the compound of formula (I) is selected from:

((5R,6S)-5-((3aS,4R,5S,7aS)-4-(aminomethyl)-7a-methyl-1-methyleneoctahydro-1H-inden-5-yl)-2-(4-methoxybenzyl)-5-methyl-4,5,6,7-tetrahydro-2H-indazol-6-yl)methanol;

((5R,6S)-5-((3aS,4R,5S,7aS)-4-(aminomethyl)-7a-methyl-1-methyleneoctahydro-1H-inden-5-yl)-2-(4-fluorobenzyl)-5-methyl-4,5,6,7-tetrahydro-2H-indazol-6-yl)methanol;

((5R,6S)-5-((3aS,4R,5S,7aS)-4-(aminomethyl)-7a-methyl-1-methyleneoctahydro-1H-inden-5-yl)-1-(4-methoxybenzyl)-5-methyl-4,5,6,7-tetrahydro-1H-indazol-6-yl)methanol; and

((5R,6S)-5-((3aS,4R,5S,7aS)-4-(aminomethyl)-7a-methyl-1-methyleneoctahydro-1H-inden-5-yl)-1-(4-fluorobenzyl)-5-methyl-4,5,6,7-tetrahydro-1H-indazol-6-yl)methanol.

14. The method of claim 11 wherein the compound of formula (I) is selected from:

((5R,6S)-5-((3aS,4R,5S,7aS)-4-(aminomethyl)-7a-methyl-1-methyleneoctahydro-1H-inden-5-yl)-2-(4,4-difluorocyclohexyl)-5-methyl-4,5,6,7-tetrahydro-2H-indazol-6-yl)methanol; and

((5R,6S)-5-((3aS,4R,5S,7aS)-4-(aminomethyl)-7a-methyl-1-methyleneoctahydro-1H-inden-5-yl)-1-(4,4-difluorocyclohexyl)-5-methyl-4,5,6,7-tetrahydro-1H-indazol-6-yl)methanol.

15. The method of claim 11 wherein the compound of formula (I) is selected from:

((5R,6S)-5-((3aS,4R,5S,7aS)-4-(aminomethyl)-7a-methyl-1-methyleneoctahydro-1H-inden-5-yl)-1-(5-fluoropyridin-2-yl)-5-methyl-4,5,6,7-tetrahydro-1H-indazol-6-yl)methanol;

((5R,6S)-5-((3aS,4R,5S,7aS)-4-(aminomethyl)-7a-methyl-1-methyleneoctahydro-1H-inden-5-yl)-1-(5-fluoropyrimidin-2-yl)-5-methyl-4,5,6,7-tetrahydro-1H-indazol-6-yl)methanol;

((5R,6S)-5-((3aS,4R,5S,7aS)-4-(aminomethyl)-7a-methyl-1-methyleneoctahydro-1H-inden-5-yl)-2-(5-fluoropyrimidin-2-yl)-5-methyl-4,5,6,7-tetrahydro-2H-indazol-6-yl)methanol; and

((5R,6S)-5-((3aS,4R,5S,7aS)-4-(aminomethyl)-7a-methyl-1-methyleneoctahydro-1H-inden-5-yl)-2-(5-fluoropyridin-2-yl)-5-methyl-4,5,6,7-tetrahydro-2H-indazol-6-yl)methanol.

16. The compound of claim 1 wherein:

is a fused 5- or 6-membered N-heteroaryl substituted by substituted aryl, substituted aralkyl, substituted cycloalkyl or substituted heteroaryl;

R 1 is hydrogen;

R 2 is —R 6 —OR 7 ;

R 3 is —R 6 —OR 7 or —R 6 —N(R 8 ) 2 ;

R 4a is alkyl and R 4b is hydrogen;

R 5 is alkyl or R 5 is a direct bond to the carbon at C14;

each R 6 is independently selected from a direct bond or a straight or branched alkylene chain;

each R 7 is independently selected from hydrogen or alkyl; and

each R 8 is independently selected from hydrogen or alkyl.

17. The method of claim 16 wherein the compound of formula (I) is selected from:

(4-((5R,6S)-5-((1 S,3aS,4S,5S,7aR)-4-(aminomethyl)-1,7a-dimethyloctahydro-1H-inden-5-yl)-6-(hydroxymethyl)-5-methyl-4,5,6,7-tetrahydro-1H-indazol-1-yl)phenyl)(phenyl)methanone;

(4-((5R,6S)-5-((1 S,3aS,4S,5S,7aR)-4-(aminomethyl)-1,7a-dimethyloctahydro-1H-inden-5-yl)-6-(hydroxymethyl)-5-methyl-4,5,6,7-tetrahydro-2H-indazol-2-yl)phenyl)(phenyl)methanone;

((5R,6S)-5-((1S,3aS,4S,5S,7aR)-4-(aminomethyl)-1,7a-dimethyloctahydro-1H-inden-5-yl)-1-(4-fluorophenyl)-5-methyl-4,5,6,7-tetrahydro-1H-indazol-6-yl)methanol;

((5R,6S)-5-((1S,3aS,4S,5S,7aR)-4-(aminomethyl)-1,7a-dimethyloctahydro-1H-inden-5-yl)-1-(4-methoxyphenyl)-5-methyl-4,5,6,7-tetrahydro-1H-indazol-6-yl)methanol;

((5R,6S)-5-((1S,3aS,4S,5S,7aR)-4-(aminomethyl)-1,7a-dimethyloctahydro-1H-inden-5-yl)-2-(4-fluorophenyl)-5-methyl-4,5,6,7-tetrahydro-2H-indazol-6-yl)methanol;

((5R,6S)-5-((1S,3aS,4S,5S,7aR)-4-(aminomethyl)-1,7a-dimethyloctahydro-1H-inden-5-yl)-2-(4-methoxyphenyl)-5-methyl-4,5,6,7-tetrahydro-2H-indazol-6-yl)methanol;

((5R,6S)-5-((1S,3aS,4S,5S,7aR)-4-(aminomethyl)-1,7a-dimethyloctahydro-1H-inden-5-yl)-2-(4-(4-fluorophenoxy)phenyl)-5-methyl-4,5,6,7-tetrahydro-2H-indazol-6-yl)methanol;

((5R,6S)-5-((1S,3aS,4S,5S,7aR)-4-(aminomethyl)-1,7a-dimethyloctahydro-1H-inden-5-yl)-1-(4-(4-fluorophenoxy)phenyl)-5-methyl-4,5,6,7-tetrahydro-1H-indazol-6-yl)methanol;

((5R,6S)-5-((1S,3aS,4S,5S,7aR)-4-(aminomethyl)-1,7a-dimethyloctahydro-1H-inden-5-yl)-1-(4-(4-fluorophenoxy)phenyl)-5-methyl-4,5,6,7-tetrahydro-1H-indazol-6-yl)methanol hydrochloride;

((5R,6S)-5-((1S,3aS,4S,5S,7aR)-4-(aminomethyl)-1,7a-dimethyloctahydro-1H-inden-5-yl)-5-methyl-2-(4-(pyridin-2-yloxy)phenyl)-4,5,6,7-tetrahydro-2H-indazol-6-yl)methanol;

((5R,6S)-5-((1S,3aS,4S,5S,7aR)-4-(aminomethyl)-1,7a-dimethyloctahydro-1H-inden-5-yl)-5-methyl-1-(4-(pyridin-2-yloxy)phenyl)-4,5,6,7-tetrahydro-1H-indazol-6-yl)methanol;

((5R,6S)-5-((1S,3aS,4S,5S,7aR)-4-(aminomethyl)-1,7a-dimethyloctahydro-1H-inden-5-yl)-5-methyl-2-(4-(pyridin-4-yloxy)phenyl)-4,5,6,7-tetrahydro-2H-indazol-6-yl)methanol;

((5R,6S)-5-((1S,3aS,4S,5S,7aR)-4-(aminomethyl)-1,7a-dimethyloctahydro-1H-inden-5-yl)-5-methyl-1-(4-(pyridin-4-yloxy)phenyl)-4,5,6,7-tetrahydro-1H-indazol-6-yl)methanol;

((5R,6S)-5-((1S,3aS,4S,5S,7aR)-4-(aminomethyl)-1,7a-dimethyloctahydro-1H-inden-5-yl)-5-methyl-1-(4-(pyrimidin-5-yloxy)phenyl)-4,5,6,7-tetrahydro-1H-indazol-6-yl)methanol; and

((5R,6S)-5-((1S,3aS,4S,5S,7aR)-4-(aminomethyl)-1,7a-dimethyloctahydro-1H-inden-5-yl)-5-methyl-2-(4-(pyrimidin-5-yloxy)phenyl)-4,5,6,7-tetrahydro-2H-indazol-6-yl)methanol.

18. The method of claim 16 wherein the compound of formula (I) is selected from:

((5R,6S)-5-((1S,3aS,4S,5S,7aR)-4-(aminomethyl)-1,7a-dimethyloctahydro-1H-inden-5-yl)-2-(4-methoxybenzyl)-5-methyl-4,5,6,7-tetrahydro-2H-indazol-6-yl)methanol; and

((5R,6S)-5-((1S,3aS,4S,5S,7aR)-4-(aminomethyl)-1,7a-dimethyloctahydro-1H-inden-5-yl)-1-(4-methoxybenzyl)-5-methyl-4,5,6,7-tetrahydro-1H-indazol-6-yl)methanol.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 23, 2022
From: HARWIG, CURTIS; PETTIGREW, JEREMY D.; CROSS, JENNIFER; SEENISAMY, JEYAPRAKASHNARAYANAN; KEREGADDE, MAHESH NARAYAN; IYANAR, KARTHIKEYAN
To: TARO PHARMACEUTICALS INC.
Reel/Frame 059989/0603 →
Continuity (3)
Continuation 17045675
Provisional Application 62654191 · Apr 6, 2018
Related Publication 20220306645A1 · Sep 29, 2022